medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 5

<< Back Next >>

Med Int Mex 2023; 39 (5)

Risk factors of mortality in patients with rhino-orbito-cerebral mucormycosis and COVID-19

Quintero BA, Lugo MJA, Sainz FN, Arellano RIC, Canche MEM, Reina LJR, Rodríguez QOS, Rodríguez RPA

Language: Spanish
References: 45
Page: 734-742
PDF size: 240.45 Kb.


ABSTRACT

Objective: To identify the risk factors associated with mortality in patients with rhinoorbito- cerebral mucormycosis and COVID-19 infection.
Materials and Methods: Observational, analytical, cross-sectional and retrospective study of patients with rhino-orbito-cerebral mucormycosis was made from January 2020 to October 2022. Descriptive statistics were applied, for the inferential analysis Mann-Whitney U and Pearson’s χ2 were used, as well as odds ratio (OR) to determine the risk, a value of p ≤ 0.05 was considered significant.
Results: Fifteen patients were included, with an average age of 60.87, 9 males. No differences were found between the living and the dead for sex, location of the mucormycosis, or the severity of COVID-19. Differences were found between the number of comorbidities (p = 0.035) and the type of surgical treatment (p = 0.039). When evaluating the risk of death and sex OR was of 0.125 (CI95% 0.009-1.723), location of the disease: OR 0.30 (CI95% 0.014-6.382), degree of disease by COVID-19: OR 10 (CI95% 0.584-171.202), stage by tomography: OR 4.500 (CI95% 0.374-54.155), type of surgical treatment: OR 13.500 (CI95% 0.878-207.624).
Conclusions: The factors associated with mortality in patients with rhino-orbitocerebral mucormycosis and COVID-19 were having two or more comorbidities and the type of surgical treatment.


REFERENCES

  1. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, SarkisovaTA, Schaufele RL, et al. Epidemiology and outcome ofzygomycosis: A review of 929 reported cases. Clin InfectDis 2005; 41 (5): 634-653. https://doi.org/10.1086/432579.

  2. Binder U, Maurer E, Lass-Flörl C. Mucormycosis - from thepathogens to the disease. Clin Microbiol Infect 2014; 20Suppl 6: 60-6. doi: 10.1111/1469-0691.12566.

  3. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, KongDCM, et al. The epidemiology and clinical manifestationsof mucormycosis: a systematic review and meta-analysisof case reports. Clin Microbiol Infect 2019; 25 (1): 26-34.doi: 10.1016/j.cmi.2018.07.011.

  4. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ,Kontoyiannis DP. Epidemiology and clinical manifestationsof mucormycosis. Clin Infect Dis 2012; 54 (Suppl. 1): S23-34.doi: 10.1093/cid/cir866.

  5. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL.The epidemiological features of invasive mycotic infectionsin the San Francisco Bay Area, 1992-1993: Results ofpopulation-based laboratory active surveillance. Clin InfectDis 1998; 27 (5): 1138-47.

  6. Nagalli S, Kikkeri NS. Mucormycosis in COVID-19: A systematicreview of literature. Infez Med 2021; 29: 504-12. doi:10.53854/liim-2904-2.

  7. Köhler JR, Hube B, Puccia R, Casadevall A, Perfect JR.Fungi that infect humans. Microbiol Spectr 2017; 5 (3).doi: 10.1128/microbiolspec.FUNK-0014-2016.

  8. Nucci M, Engelhardt M, Hamed K. Mucormycosis in SouthAmerica: A review of 143 reported cases. Mycoses 2019;62: 730-8. doi: 10.1111/myc.12958.

  9. Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E,Petrikkos G. Challenges in the diagnosis and treatmentof mucormycosis. Med Mycol 2018; 56: S93-101. doi:

  10. 10.1093/mmy/myx101.10. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis.J Fungi 2019; 5 (1): 26. doi: 10.3390/jof5010026.

  11. Steinbrink JM, Miceli MH. Mucormycosis. Infect Dis ClinNorth Am 2021; 35: 435-52. doi: 10.1016/j.idc.2021.03.009.

  12. Petrikkos G, Tsioutis C. Recent advances in the pathogenesisof mucormycoses. Clin Ther Excerpta Medica 2018; 40:894-902. doi: 10.1016/j.clinthera.2018.03.009.

  13. Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis—The bitter and the sweet. PLoS Pathog 2017; 13. doi:10.1371/journal.ppat.1006408.

  14. Roilides E, Antachopoulos C, Simitsopoulou M. Pathogenesisand host defense against Mucorales: The role ofcytokines and interaction with antifungal drugs. Mycoses2014; 57 (s3): 40-7. doi: 10.1111/myc.12236.

  15. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis(mucormycosis): emerging clinical importance and newtreatments. Curr Opin Infect Dis 2004; 17 (6): 517-25. doi:10.1097/00001432-200412000-00003.

  16. World Health Organization. Director-General’s remarks atthe media briefing on 2019-nCoV on 11 February 2020.https://www.who.int/es/director-general/speeches/detail/who-director-general-s-remarks-at-the-mediabriefing-on-2019-ncov-on-11-february-2020. 2020.

  17. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C,Gulyaeva AA, et al. The species severe acute respiratorysyndrome-related coronavirus: classifying 2019-nCoV andnaming it SARS-CoV-2. Nature Microbiol 2020; 5: 536-44.https://doi.org/10.1038/s41564-020-0695-z.

  18. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, HerrlerT, Erichsen S, et al. SARS-CoV-2 cell entry depends onACE2 and TMPRSS2 and is blocked by a clinically provenprotease inhibitor. Cell 2020; 181 (2): 271-280.e8. doi:10.1016/j.cell.2020.02.052.

  19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinicalfeatures of patients infected with 2019 novel coronavirus inWuhan, China. Lancet 2020; 395 (10223): 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.

  20. Hussain S, Riad A, Singh A, Klugarová J, Antony B, Banna H,et al. Global prevalence of COVID-19-associated mucormycosis(CAM): Living systematic review and meta-analysis. JFungi 2021; 7 (11). doi: 10.3390/jof7110985.

  21. Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I,Sharma R, et al. Multicenter epidemiologic study of coronavirusdisease-associated mucormycosis, India. Emerg InfectDis 2021; 27 (9): 2349-59. doi: 10.3201/eid2709.210934.

  22. Nucci M, Engelhardt M, Hamed K. Mucormycosis in SouthAmerica: A review of 143 reported cases. Mycoses 2019;62: 730-8. doi: 10.1111/myc.12958.

  23. Code Mucor: Guidelines for the Diagnosis, Staging andManagement of Rhino-Orbito-Cerebral Mucormycosis inthe Setting of COVID-19. 2021.

  24. Janjua OS, Shaikh MS, Fareed MA, Qureshi SM, Khan MI,Hashem D, et al. Dental and oral manifestations of COVID-19 related mucormycosis: diagnoses, managementstrategies and outcomes. J Fungi 2022; 8: 44. doi: 10.3390/jof8010044.

  25. Pippal SK, Kumar D, Ukawat L. Management challengeof rhino-orbito-cerebral mucormycosis in Covid 19 era: aprospective observational study. Indian J Otolaryngol HeadNeck Surgery 2022; 74 (Suppl 2): 3485-3491.; doi: 10.1007/s12070-021-02947-5.

  26. Safi M, Ang MJ, Patel P, Silkiss RZ. Rhino-orbital-cerebralmucormycosis (ROCM) and associated cerebritis treatedwith adjuvant retrobulbar amphotericin B. Am J OphthalmolCase Rep. 2020; 19. doi: 10.1016/j.ajoc.2020.100771.

  27. Lee AS, Lee PWY, Allworth A, Smith T, Sullivan TJ. Orbitalmycoses in an adult subtropical population. Eye (Basingstoke).2020; 34 (9): 1640-7. https://doi.org/10.1038/s41433-019-0733-3.

  28. Satish D, Joy D, Ross A, Balasubramanya. Mucormycosis coinfectionassociated with global COVID-19: a case series fromIndia. Int J Otorhinolaryngol Head Neck Surg 2021; 7 (5).

  29. Fouad YA, Abdelaziz TT, Askoura A, Saleh MI, Mahmoud MS,Ashour DM, et al. Spike in rhino-orbital-cerebral mucormycosiscases presenting to a tertiary care center during theCOVID-19 pandemic. Front Med (Lausanne) 2021; 8. doi:10.3389/fmed.2021.645270.

  30. Ashour MM, Abdelaziz TT, Ashour DM, Askoura A, Saleh MI,Mahmoud MS. Imaging spectrum of acute invasive fungalrhino-orbital-cerebral sinusitis in COVID-19 patients: A caseseries and a review of literature. J Neuroradiol 2021; 48(5). doi: 10.1016/j.neurad.2021.05.007.

  31. Bayram N, Ozsaygılı C, Sav H, Tekin Y, Gundogan M, PangalE, et al. Susceptibility of severe COVID-19 patients torhino-orbital mucormycosis fungal infection in differentclinical manifestations. Jpn J Ophthalmol 2021; 65 (4). doi:10.1007/s10384-021-00845-5.

  32. Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, MehrparvarG, et al. Mucormycosis in patients with COVID-19:A cross-sectional descriptive multicentre study from Iran.Mycoses 2021; 64 (10). doi: 10.1111/myc.13334.

  33. Guzmán-Castro S, Chora-Hernandez LD, Trujillo-Alonso G,Calvo-Villalobos I, Sanchez-Rangel A, Ferrer-Alpuin E, et al.COVID-19–associated mucormycosis, diabetes and steroidtherapy: Experience in a single centre in Western Mexico.Mycoses 2022; 65 (1): 65-70. doi: 10.1111/myc.13383.

  34. Soni S, Namdeo Pudake R, Jain U, Chauhan N. A systematicreview on SARS-CoV-2-associated fungal coinfections. JMed Virol 2022; 94: 99-109. doi: 10.1002/jmv.27358.

  35. Rabagliati R, Rodríguez N, Núñez C, Huete A, Bravo S,Garcia P. Covid-19-associated mold infection in critically illpatients, Chile. Emerg Infect Dis 2021; 27 (5). doi: 10.3201/eid2705.204412.

  36. Mishra N, Mutya VSS, Thomas A, Rai G, Reddy B, M. AA,et al. A case series of invasive mucormycosis in patientswith COVID-19 infection. Int J Otorhinolaryngol Head NeckSurg 2021; 7 (5). https://doi.org/10.18203/issn.2454-5929.ijohns20211583.

  37. Yadav H, Sen S, Nath T, Mazumdar S, Jain A, Verma P, etal. Analysis of COVID-19-associated rhino-orbital-cerebralmucormycosis patients in a tertiary care center in NorthernIndia. Indian J Ophthalmol 2022; 70 (6): 2163-8. DOI:10.4103/ijo.IJO_340_22.

  38. Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK,Kale PG, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids—an unholy trinity in invasive fungal infectionsof the maxillofacial region? A retrospective, multi-centricanalysis. J Maxillofac Oral Surg 2021; 20 (3). doi: 10.1007/s12663-021-01532-1.

  39. Sekaran A, Patil N, Sabhapandit S, Sistla SK, Reddy DN.Rhino-orbito-cerebral mucormycosis: an epidemic in apandemic. IJID Regions 2022; 2. https://doi.org/10.1016/j.ijregi.2021.12.009.

  40. Gandhi A, Narula A, Chandra S, Agarwal D, Mehta A, NayakS, et al. Battling the emerging epidemic of rhino-orbitalcerebralmucormycosis (ROCM) in COVID-19 pandemic: aninterventional study. Int Ophthalmol 2022; 43 (5): 1571-1580. doi: 10.1007/s10792-022-02556-3.

  41. Kangro K, Wolberg AS, Flick MJ. Fibrinogen, fibrin, andfibrin degradation products in COVID-19. Curr Drug Targets2022; 23 (17): 1593-1602. doi: 10.2174/1389450123666220826162900.

  42. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis inCOVID-19: A systematic review of cases reported worldwideand in India. Diabetes Metab Syndr 2021; 15 (4). doi:10.1016/j.dsx.2021.05.019.

  43. Riad A, Shabaan AA, Issa J, Ibrahim S, Amer H, Mansy Y, etal. COVID-19-associated mucormycosis (Cam): Case-seriesand global analysis of mortality risk factors. J Fungi 2021;7 (10). doi: 10.3390/jof7100837.

  44. Zirpe K, Pote P, Deshmukh A, Gurav SK, Tiwari AM, SuryawanshiP. A retrospective analysis of risk factors of COVID-19associated mucormycosis and mortality predictors: Asingle-center study. Cureus 2021; 13 (10): e18718. doi:10.7759/cureus.18718.

  45. Bhatt K, Agolli A, H. Patel M, Garimella R, Devi M, GarciaE, et al. High mortality co-infections of COVID-19 patients:mucormycosis and other fungal infections. Discoveries2021; 9 (1): e126. doi: 10.15190/d.2021.5.




2020     |     www.medigraphic.com